RePORT International Resources

This webinar recording from TB Net occurred in July 2025.

Implementation research (IR) is important for designing strategies or solutions to overcome bottlenecks that prevent proven and innovative public health interventions from reaching the people who need them. This ensure that these interventions are used in a manner that results in the outcome for which they were intended. Such solutions include how to overcome barriers to adoption of drugs, diagnostics or preventive measures that improve health for people at risk of malaria, tuberculosis, NTDs or other infectious diseases. IR can help to ensure that health solutions reach the people who need them and are used in ways that generate intended results. This course is a step-by-step online training for public health researchers and decision-makers, disease control programme managers, academics and others that focuses on how to design and demonstrate robust IR projects to improve control of infectious diseases of poverty and generate better health outcomes.

TDR supports effective and innovative global health research, through strengthening the research capacity of disease-affected countries, and promoting the translation of evidence into interventions that reduce the burden of infectious diseases and build resilience in the most vulnerable populations

TDR's catalogue of online courses in implementation research (IR)

Can assess all the 13th IAS Conference on HIV Science at this website

The Antibacterial Resistance Leadership Group (ARLG) invites requests for industry collaboration from the ARLG in the form of advice, guidance, protocol design for drug, device, or diagnostic development. The ARLG develops, designs, implements, and manages a clinical research agenda to increase knowledge of antibacterial resistance (AR). The ARLG aims to advance research by building transformational trials that will change clinical practice and reduce the impact of antibacterial resistance and antimicrobial resistance through the following strategies: - Early clinical evaluation of new antibacterials; - Comparative effectiveness or efficacy trials; - Strategy trials to optimize currently licensed antibacterials (dose, duration, need for drug) to reduce the risk of resistance; - Clinical algorithm testing strategies; - Treatment-based prevention measures; - Diagnostics testing in the context of treatment trials, epidemiologic elements, or behavioral modification; - Effective infection control programs which include surveillance for resistant organisms, outbreak investigation, and antibiotic stewardship to prevent the development and spread of resistant organisms; - Novel facilities level activities to prevent the development of resistance.

In 1974, the US National Research Act was signed into law, there-by creating the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. One of the charges to the Commission was to identify the basic ethical principles that should underlie the conduct of biomedical and behavioral research involving human subjects and to develop guidelines which should be followed to assure that such research is conducted in accordance with those principles. In carrying out the above, the Commission was directed to consider: (i) the boundaries between biomedical and behavioral research and the accepted and routine practice of medicine, (ii) the role of assessment of risk-benefit criteria in the determination of the appropriateness of research involving human subjects, (iii) appropriate guidelines for the selection of human subjects for participation in such research and (iv) the nature and definition of informed consent in various research settings. The Belmont Report attempts to summarize the basic ethical principles identified by the Commission in the course of its deliberations.

This Crash Course video, The Deadliest Infectious Disease of All Time, explores the history, biology, and global impact of TB. From its ancient origins to its ongoing role as a leading cause of infectious death worldwide, the video examines how TB spreads, why it remains so deadly, and how social and political factors shape its burden. Engaging and informative, the episode highlights both scientific advances and enduring health inequities.

The 2025 Results Report is a snapshot of the partnerships' progress in the fight to end AIDS, TB and malaria during 2024.

The Global Health Network aims to strengthen health research in underserved areas by: Supporting and streamlining research where evidence is lacking. Promoting equity in participation and access to research benefits through open sharing of knowledge and data. Building sustainable, skilled research teams in low-resource settings capable of leading and competing globally.

COURSE PERIOD: November 2025 and February 2026. Biomedical research increasingly depends on the responsible collection, management, and reuse of large datasets and biological samples. This course introduces the principles and practices of data and sample governance to ensure that biomedical resources are managed ethically, legally, and effectively, while enabling their reuse for future research and innovation. The course comprises four discovery learning modules released monthly between November 2025 and February 2026. Each module includes short expert lectures, infographics, case studies, and interactive materials. Participants who complete all modules will receive a Certificate of Completion, issued by ESCMID.

New course - free and online - An Introduction and Practical Guide to Community Engagement and Involvement in Global Health Research

Good Clinical Laboratory Practice (GCLP) is a set of guidelines describing the application of those Good Laboratory Practice principles that are relevant to the analyses of samples from clinical trials while ensuring the purpose and objectives of the Good Clinical Practice principles are maintained. In so doing, the reliability, quality, consistency and integrity of data generated by clinical trial laboratories can be assure which is crucial to the outcome of any clinical trial.

This ICH E6 GCP Investigator Site Training, in multiple languages, meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerate BioPharma as necessary to enable mutual recognition of GCP training among trial sponsors.

New course - free and online - Research Ethics Online Training (V2)

The templates have been shared by groups, and are free to use and adapt for individual's research studies.

Date: 29 January, 2026 This webinar will provide an overview of MICROBE, an interactive visualisation platform developed by the Institute for Health Metrics and Evaluation (IHME), enabling exploration of global antimicrobial resistance (AMR) burden estimates and comparison across pathogens, drug classes, and geographies. Other open-access tools will be discussed, including the World Health Organization's Global Antimicrobial Resistance and Use Surveillance System (GLASS) and the AMR R package. The AMR Data Repository, a new platform co-launched by the Global Research on Antimicrobial Resistance (GRAM) Project and the Infectious Diseases Data Observatory (IDDO) which curates high-value datasets, expands access for researchers, particularly in low and middle-income countries, and supports ethical data reuse, will also be introduced.

DEADLINE: January 2026 SEPTRE (SPIRIT Electronic Protocol Tool and Resource) is an innovative, web-based software solution that makes it easier to create, manage, and register high-quality protocols for clinical trials. From now until January 2026, The Global Health Network and EDCTP have a limited number of free individual three-year SEPTRE licenses for researchers based in low-resource settings.

The PHA Editors will consider any manuscript reporting original research on progress to achieving the SDGs. Suitable topics include infection-related topics such as vaccines, infection prevention control, outbreaks and antimicrobial resistance. Non-communicable diseases of public health importance include nutrition, the impact of climate change and planetary health. The journal aims to improve public health practice and we welcome operational research, lessons from implementation and evaluations of public health interventions. We will also consider submissions that focus on issues related to health care access and universal health coverage, quality, efficiency, cost-effectiveness, ethics and equity as well as education and training.